Michael White, Rogerio Amino, Ivo Mueller  Trends in Parasitology 

Slides:



Advertisements
Similar presentations
Malaria Dept. of Infectious Disease Shengjing Hospital CMU.
Advertisements

Genome Engineering with CRISPR-Cas9 in the Mosquito Aedes aegypti
Malaria By: Keri Gregory. What is Malaria??? Malaria is an infectious disease that is cause by a protozoan parasite.
Irreplaceability of Neuronal Ensembles after Memory Allocation Naoki Matsuo Cell Reports Volume 11, Issue 3, Pages (April 2015) DOI: /j.celrep
Wilderness in the ‘city’ revisited: different urbes shape transmission of Echinococcus multilocularis by altering predator and prey communities Stefano.
Malaria parasite (plasmodium)
Genus: Malaria parasites. The malaria parasites are protozoan parasites, belong to the family plasmodium, and classified into many species. The plasmodium.
DEFINITIONS Infection: – The entry, development and multiplication of an infectious agent in the body of humans or animals. The result may be: inapparent.
Malaria Dept. Infectious Disease 2nd Affiliated Hospital CMU.
MALARIA. A vector-borne infectious disease Caused by protozoan parasites of the genus Plasmodium Plasmodium falciparum and Plasmodium vivax P.ovale, P.malariae.
Foundation Block Introduction to Parasitology Foundation Block,
Two views of brain function Marcus E. Raichle Trends in Cognitive Sciences Volume 14, Issue 4, Pages (April 2010) DOI: /j.tics
2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.
Date of download: 6/29/2016 Copyright © 2016 McGraw-Hill Education. All rights reserved. Life cycle of Plasmodium vivax, the agent of vivax (tertian) malaria.
Malaria Amal Hassan.
Life cycle of Plasmodium vivax, the agent of vivax (tertian) malaria
Volume 14, Issue 8, Pages (December 2011)
National Guidelines for Nursing Delegation
ARULANANDAM TERENCE.T 403(A)
Irene N. Nkumama, Wendy P. O’Meara, Faith H.A. Osier 
Biology of Plasmodium ZLY 201
Biology of Plasmodium ZLY 201
Life cycle of Plasmodium vivax, the agent of vivax (tertian) malaria
C.-S. Lee, J.-H. Lee  Clinical Microbiology and Infection 
Plasmodium Life Cycle Mark F. Wiser
Biodiversity, cultural pathways, and human health: a framework
Malarial life cycle… Dr.Shelke A.N. Assist.professor
The prevention of canine leishmaniasis and its impact on public health
Influenza vaccination and Guillain-Barré syndrome
The onchocerciasis chronicle: from the beginning to the end?
Malaria Vaccines: Recent Advances and New Horizons
M.L. McMorrow, M. Aidoo, S.P. Kachur 
Michael Paul, Lonnie King, Ellen P. Carlin  Trends in Parasitology 
Cervical cancer incidence can increase despite HPV vaccination
Clinical characteristics of Haemophilus influenzae meningitis in Denmark in the post- vaccination era  T.I. Pedersen, M. Howitz, C. Østergaard  Clinical.
C.-S. Lee, J.-H. Lee  Clinical Microbiology and Infection 
Malaria Vaccine Design: Immunological Considerations
Malaria vaccines and the new malaria agenda
Julie Jacobson, Simon Bush  Trends in Parasitology 
How to Contain Artemisinin- and Multidrug-Resistant Falciparum Malaria
Louis Pasteur, from crystals of life to vaccination
How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development  R. Bax  Clinical Microbiology.
General infection control issues
Irene N. Nkumama, Wendy P. O’Meara, Faith H.A. Osier 
Rising food insecurity in Europe
How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemiologic approach  D. Guillemot  Clinical Microbiology.
Trends in antibiotic prescribing in general internal medicine wards: antibiotic use and indication for prescription  B. Maraha, M. Bonten, H. Fiolet,
Human infections with Plasmodium knowlesi—zoonotic malaria
Malaria: New Vaccines for Old?
Towards the risk of yellow fever transmission in Europe
P.L. Lopalco, P. Carrillo Santisteve 
Michael Charlton  Clinical Gastroenterology and Hepatology 
Trends in Microbiology
Rotavirus vaccination: a concise review
Pathogenic Protozoa.
Pharmacology 3 antimalarial drugs lecture 11 by Prof.Dr. Mohamed Fahmy
Zika Virus in the Americas: A Review for Clinicians
Hannah C. Slater, Lucy C. Okell, Azra C. Ghani  Trends in Parasitology 
Uniting mathematics and biology for control of visceral leishmaniasis
Suppression of malaria vector densities and human infection prevalence associated with scale-up of mosquito-proofed housing in Dar es Salaam, Tanzania:
Amy B. Pedersen, Andy Fenton  Trends in Parasitology 
Clinical Microbiology and Infection
Daniel Reinhardt, MD, Michael Bokempber, MD, Jacob Brubacher, MD, E
Facilitating learning and change in physicians: Implications for a system of continuing medical education in Europe  Robert D. Fox  Clinical Microbiology.
Organization news Archives of Physical Medicine and Rehabilitation
Clinical microbiological case: thermointolerant microorganism growth in blood cultures and catheter tip  M. Blasco-Navalpotro, M. Jordán, J.J. Camarena,
Spatial change in the risks of Plasmodium vivax and Plasmodium falciparum malaria in China, 2005–2014  Samuel Hundessa, Gail Williams, Wenyi Zhang, Shanshan.
Nicole Mideo, Sarah E. Reece, Adrian L. Smith, C. Jessica E. Metcalf 
Cricoid pressure force retention analysis using a simulator
Introduction to OpenMalaria
Presentation transcript:

Theoretical Implications of a Pre-Erythrocytic Plasmodium vivax Vaccine for Preventing Relapses  Michael White, Rogerio Amino, Ivo Mueller  Trends in Parasitology  Volume 33, Issue 4, Pages 260-263 (April 2017) DOI: 10.1016/j.pt.2016.12.011 Copyright © 2017 The Authors Terms and Conditions

Figure 1 Example of a Bite from a Plasmodium vivax Infectious Mosquito Inoculating 15 Sporozoites Consisting of 10 Tachysporozoites That Immediately Develop into Exoerythrocytic Schizonts, and 5 Bradysporozoites That Develop into Hypnozoites.--> In an unvaccinated individual, the 10 tachysporozoites will cause a single primary blood-stage infection, and the hypnozoites will cause up to five relapses. Some hypnozoites may die within liver hepatocytes or activate in batches, giving rise to fewer than five relapses. In an individual receiving a vaccine that immobilises 90% of sporozoites, the efficacy against primary infection will be 0.910=35%. However, every hypnozoite immobilised may potentially lead to a relapse prevented, and consequently an efficacy against relapses of up to 90%. Trends in Parasitology 2017 33, 260-263DOI: (10.1016/j.pt.2016.12.011) Copyright © 2017 The Authors Terms and Conditions

Figure 2 Simulations from a Mathematical Model of the Impact of a Hypothetical Nonwaning Pre-Erythrocytic Plasmodium vivax Vaccine. (A) By preventing infection, a vaccine can reduce the expected duration of blood-stage parasitemia. Efficacy against primary infection of Vinf=50% and duration of each blood-stage infection (primary or relapse) of 1 month are assumed. The dashed line indicates the expected duration of blood-stage parasitemia in an unvaccinated individual. (B) Predicted impact of a vaccination campaign with 70% coverage on population-level transmission. The R computer code for generating this figure is provided in the, supplemental information online allowing for simulation with different parameter values. Trends in Parasitology 2017 33, 260-263DOI: (10.1016/j.pt.2016.12.011) Copyright © 2017 The Authors Terms and Conditions